Royalty Pharma plc Files 8-K: Material Agreement & Financials
Ticker: RPRX · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $600 million, $900 million, $500 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financials, 8-k
TL;DR
Royalty Pharma signed a big deal, filed financials. Watch this space.
AI Summary
On September 16, 2025, Royalty Pharma plc entered into a material definitive agreement. The filing also indicates other events and the submission of financial statements and exhibits. The company's principal executive offices are located at 110 East 59th Street, New York, NY 10022.
Why It Matters
This 8-K filing signals a significant new agreement for Royalty Pharma plc, which could impact its future revenue streams and strategic direction. Investors should monitor the details of this agreement for potential financial implications.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which inherently carries business and financial risks that are not fully detailed in this summary.
Key Players & Entities
- Royalty Pharma plc (company) — Registrant
- September 16, 2025 (date) — Date of earliest event reported
- 110 East 59th Street, New York, NY 10022 (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Royalty Pharma plc?
The filing states that Royalty Pharma plc entered into a material definitive agreement on September 16, 2025, but the specific details of this agreement are not provided in the summary.
What other events are reported in this 8-K filing?
The filing indicates 'Other Events' as a category, but the specific details of these events are not elaborated upon in the provided text.
What financial statements and exhibits are being filed?
The filing lists 'Financial Statements and Exhibits' as an item, but the content of these documents is not detailed in the provided summary.
When was this 8-K form filed?
This 8-K form was filed on September 16, 2025.
Where are Royalty Pharma plc's principal executive offices located?
Royalty Pharma plc's principal executive offices are located at 110 East 59th Street, New York, New York 10022.
Filing Stats: 1,193 words · 5 min read · ~4 pages · Grade level 9.6 · Accepted 2025-09-16 16:05:47
Key Financial Figures
- $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
- $600 million — announced offering (the "Offering") of $600 million aggregate principal amount of 4.450% Se
- $900 million — nior Notes due 2031 (the "2031 Notes"), $900 million aggregate principal amount of 5.200% Se
- $500 million — r Notes due 2035 (the "2035 Notes") and $500 million aggregate principal amount of 5.950% Se
Filing Documents
- d58607d8k.htm (8-K) — 32KB
- d58607dex11.htm (EX-1.1) — 236KB
- d58607dex43.htm (EX-4.3) — 182KB
- d58607dex51.htm (EX-5.1) — 16KB
- d58607dex52.htm (EX-5.2) — 65KB
- g58607g0909091354148.jpg (GRAPHIC) — 2KB
- 0001193125-25-204983.txt ( ) — 755KB
- rprx-20250916.xsd (EX-101.SCH) — 3KB
- rprx-20250916_lab.xml (EX-101.LAB) — 17KB
- rprx-20250916_pre.xml (EX-101.PRE) — 11KB
- d58607d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 1.1 Underwriting Agreement, dated as of September 2, 2025, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein. 4.1 Indenture, dated as of September 2, 2020, among Royalty Pharma plc, Royalty Pharma Holdings Ltd and Wilmington Trust, National Association, as Trustee (incorporated herein by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K (File No. 001-39329), filed with the SEC on September 2, 2020). 4.2 Fourth Supplemental Indenture, dated as of June 9, 2025, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as Trustee (incorporated herein by reference to Exhibit 10.6 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-39329), filed with the SEC on August 6, 2025). 4.3 Fifth Supplemental Indenture, dated as of September 16, 2025, among Royalty Pharma plc, Royalty Pharma Holdings Ltd, Royalty Pharma Manager, LLC and Wilmington Trust, National Association, as Trustee. 4.4 Form of 4.450% Senior Notes due 2031 (included in Exhibit 4.3 hereto). 4.5 Form of 5.200% Senior Notes due 2035 (included in Exhibit 4.3 hereto). 4.6 Form of 5.950% Senior Notes due 2055 (included in Exhibit 4.3 hereto). 5.1 Opinion of Davis Polk & Wardwell LLP with respect to the Securities. 5.2 Opinion of Davis Polk & Wardwell London LLP with respect to certain matters of English law. 23.1 Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1). 23.2 Consent of Davis Polk & Wardwell London LLP (included in Exhibit 5.2). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 16, 2025 ROYALTY PHARMA PLC By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer